Average payments for GLP-1 weight-loss medications among people without diabetes rose 157% between 2017 and 2022, according to a Northwestern University study. Employers and insurers are paying more, the authors said, and those costs are passed on to consumers. The analysis discloses no…
Average payments for GLP-1 weight-loss drugs among people without diabetes rose 157% between 2017 and 2022, according to a Northwestern University study. The study authors said employers and insurers are paying more for the medications, and those costs are passed on to consumers. The figure is a new quantitative estimate of spending growth for a peptide class that has become a major and closely watched category of drug expenditure in American health benefits.
Use of GLP-1 weight-loss drugs has grown among Americans over the same period, and the payment data track that growth. The 157% figure captures average payments, not list prices and not prescription counts. The five-year window runs from 2017 to 2022, a span that brackets the entry of once-weekly GLP-1 weight-loss therapy into the US market, and it ends at a point where the class had become a routine subject of employer health plan debate.
For the peptide research community the number is more than a billing statistic. GLP-1 drugs are peptide-based therapies, and cost and access trends for non-diabetic weight-loss use now shape clinical adoption and reimbursement decisions across the peptide field. Pipeline investment, manufacturing scale-up, and formulary strategy all track payment signals of this kind. When the average payer outlay on a drug class rises 157% in five years, formularies, prior authorization rules, and patient cost-sharing obligations all move in response.
The study does not disclose its methodology, sample size, or the specific drugs and doses it counted. What it does establish is direction and scale: over five years, average payments for GLP-1 weight-loss medications in a population without diabetes grew to more than two and a half times their 2017 level, and the burden of that growth falls, in the authors' telling, on employers, insurers, and ultimately consumers.
The Northwestern University analysis examined average payments for GLP-1 weight-loss drugs among people without diabetes from 2017 to 2022. The study authors said employers and insurers are paying more, and those costs are passed on to consumers. No baseline payment amount is provided, so the 157% increase is the complete quantitative picture the study offers.
The summary identifies no specific GLP-1 medications. It does not name doses, patient demographics, or payer categories, and it does not state whether the underlying data come from commercial insurance claims, Medicare, Medicaid, pharmacy benefit manager records, or some combination. A 157% increase in average payments can emerge from any mix of three forces: rising prices per prescription, rising prescription volume, and a shift from older, lower-cost agents to newer, higher-price agents. The study as summarized cannot separate them. These limits extend to the two additional studies described below; none of the three reports methods, sample sizes, effect sizes, confidence intervals, p-values, or funding sources.
What the authors did state is the distributional outcome. When average payments rise this steeply, the initial cost lands on the employers and insurers that pay the claims, and claim costs flow into premiums, formulary tiers, copayments, coinsurance, and deductibles. The summary does not report whether patient out-of-pocket costs were measured separately from employer and insurer payments, so the consumer share of the 157% increase is not quantified. Plan responses to a cost increase of this size typically include step therapy, quantity limits, and formulary tiers that push patients toward specific products, and none of those responses is visible in the payment average itself.
Compounded over five years, a 157% cumulative increase implies an average annual growth rate near 21%. For a single therapeutic class in a defined patient population, that pace is high relative to general prescription drug spending, and it raises the policy stakes. Whatever drove the growth, the trajectory itself is now a budget line that plan sponsors cannot ignore.
The design of the Northwestern University study is not specified in the source. What is known is narrow: the population was people without diabetes taking GLP-1 weight-loss medications, the duration was 2017 to 2022, and the endpoint was average payments for those medications. Sample size is not reported.
Payment analyses of this kind, when built on insurance claims or pharmacy dispensing data, measure what was actually reimbursed rather than what was listed in a price catalog. That makes them a better gauge of real spending than list price alone. But the absence of a described methodology means the reader cannot assess how the average was constructed, whether the data were complete, or whether the result would survive adjustment for patient characteristics.
What the design cannot demonstrate is equally important. It cannot separate price inflation from utilization growth. It cannot identify which drug or dose drove the change. It cannot show whether the non-diabetic population taking these drugs shifted over the period in ways that affect the average, such as toward younger patients, older patients, or patients with different obesity severity. A change in who takes a drug changes the average payment even when prices and volumes are unchanged.
The episode is a reminder about evidence standards. A cost signal this strong, without an accompanying methods document, supports a headline but not a policy decision. Price controls, coverage restrictions, and manufacturing investment all require knowing the components of the 157%, and the study as summarized does not supply them. A companion analysis that reported the distribution of payments, not just the mean, would also show whether the typical patient's cost tracked the average or whether a minority of high-cost claims drove the figure.
GLP-1, glucagon-like peptide-1, is an incretin hormone released by intestinal L cells after food intake. It amplifies glucose-stimulated insulin secretion from pancreatic beta cells, suppresses glucagon release, slows gastric emptying, and acts on GLP-1 receptors in the hypothalamus and brainstem to reduce appetite. Native GLP-1 survives only minutes in circulation because the enzyme DPP-4 cleaves it rapidly, so the drugs that exploit this pathway are engineered peptides with modifications that resist degradation and extend half-life from minutes to days.
The marketed agents are all peptides. Liraglutide is an acylated GLP-1 analog. Semaglutide is a longer-acting derivative. Tirzepatide is a dual agonist at the GIP and GLP-1 receptors. The weight-loss effect of these molecules follows from the same biology that makes them glucose-lowering drugs: central appetite suppression, delayed gastric emptying, and reduced food reward. In a person without diabetes, the relevant clinical effects are weight loss and improved metabolic parameters, with low hypoglycemia risk because insulin secretion remains glucose-dependent. The shift toward once-weekly agents with higher per-dose peptide content is one plausible contributor to rising average payments, although the Northwestern study does not test that hypothesis.
The economics of the class follow from its chemistry. Peptides are not small molecules. They are manufactured by solid-phase or recombinant synthesis, purified to high specification, and formulated as injectables. The manufacturing base for peptide active pharmaceutical ingredients is smaller and slower to expand than the base for small-molecule production, so demand surges translate into capacity constraints and, eventually, into the payments employers and insurers see. The 157% rise in average payments among non-diabetic patients is, in part, a market signal of that capacity pressure.
The non-diabetic context matters for a second reason. Weight-loss indications were historically reimbursed less consistently than diabetes indications, because many plans treated obesity as a lifestyle condition rather than a disease. The growth captured by the Northwestern study indicates that the coverage barrier is yielding. That shift gives peptide manufacturers a larger addressable market and gives payers a new durable cost category, and it changes the risk calculus on both sides of the negotiation.
For employers and insurers, a 157% increase in average payments among people without diabetes is a budgeting event. Group health plans that cover weight-loss drugs have watched GLP-1 claims move from a minor line item to one of the largest components of pharmacy spending. The authors said those costs are passed on to consumers, which in practice means higher premiums, higher cost-sharing, or both, depending on plan design.
For clinicians, the trend changes the prescribing conversation. A physician recommending a GLP-1 drug for a patient without diabetes must now weigh not only efficacy and side effects but also whether the patient's plan covers the drug, what the prior authorization requirements are, and what the patient will pay out of pocket. Documentation of obesity as a diagnosis, rather than a cosmetic concern, has become part of the coverage negotiation for these drugs, and payment data of this kind feed directly into those decisions. The study does not quantify the out-of-pocket burden, but the cost pass-through the authors describe places it on the patient side of the ledger.
For the peptide supply chain, the figure is a planning input. If average payments for non-diabetic use rose 157% in five years, the underlying demand for peptide active pharmaceutical ingredients has grown on a similar or steeper curve, depending on the price-volume mix. The supply constraints that periodically appear in shortage records for this class illustrate how quickly demand can outrun manufacturing capacity. Manufacturers deciding whether to build additional capacity, contract development organizations deciding whether to add peptide production lines, and suppliers of amino acids and resins all read figures like this as evidence of sustained demand.
For researchers, the gap in the study is an opening. The questions it leaves unanswered, which drug, which dose, which payer, price versus volume, out-of-pocket share, are all answerable with claims-level data. A study that decomposes the 157% and reports the distribution of payments across patients and payers would turn a headline into a planning document, because each component implies a different response: a formulary change for product mix, a contract negotiation for price, a population health program for volume. For peptide manufacturers, the same decomposition determines whether capacity investments match sustained demand or a temporary surge. Until those answers are published, the 157% remains a true but incomplete measure of how this class is changing American drug spending.
A separate study conducted in Scotland examined whether epidural analgesia during labor carries neurological risk for the infant. The researchers found that babies born to women who received epidurals did not show higher rates of serious neurological conditions, cerebral palsy, or death. The study team said the evidence strongly indicates that epidurals are safe and effective pain relief for mothers.
The question has a biological rationale worth examining. Epidural analgesia works by delivering local anesthetic, often combined with a low dose of opioid, into the epidural space surrounding the spinal cord, blocking nerve transmission from the lower half of the body. The technique is effective at relieving labor pain, but it can lower maternal blood pressure and…
Peptides referenced: Semaglutide, Tirzepatide, Liraglutide, Glucagon, GLP-1.
Related reading: Wendell woman's GLP-1 overdose leads to hospital stay, $9,000 bill, GLP-1 Drug Use Reshapes Ingredient Strategy for Food and Beverage Makers, GLP-1 Drug Costs Push Dallas Health Plan Over Budget, Crocin II Targets ANGPTL8 to Reduce MASLD Progression in Preclinical Study.